Showing results (1-10 of 19) with videos related to
Sort By:
Pageof 2
Handbook of Experimental Pharmacology|September 9, 2018
Responding to New Psychoactive Substances in the European Union: Early Warning, Risk Assessment, and Control MeasuresMichael Evans-Brown, Roumen SedefovSubstance Use & Misuse|February 10, 2010
Legal highs on the InternetJennifer Hillebrand, Deborah Olszewski, Roumen SedefovEuropean Addiction Research|May 11, 2012
Misuse of medicines in the European Union: a systematic review of the literatureAlicia Casati, Roumen Sedefov, Tim Pfeiffer-GerschelDrug Testing and Analysis|June 22, 2017
Assessing the toxicological significance of new psychoactive substances in fatalitiesSimon Elliott, Roumen Sedefov, Michael Evans-BrownClinical Toxicology (Philadelphia, Pa.)|February 7, 2015
Prevalence of use and acute toxicity associated with the use of NBOMe drugsDavid M Wood, Roumen Sedefov, Andrew Cunningham, et al.Drug Testing and Analysis|July 15, 2011
The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone)Paul I Dargan, Roumen Sedefov, Ana Gallegos, et al.The International Journal on Drug Policy|March 8, 2018
Drug supply indicators: Pitfalls and possibilities for improvements to assist comparative analysisNicola Singleton, Andrew Cunningham, Teodora Groshkova, et al.The International Journal on Drug Policy|February 21, 2018
Drug affordability-potential tool for comparing illicit drug marketsTeodora Groshkova, Andrew Cunningham, Luis Royuela, et al.Journal of Addiction Medicine|May 31, 2020
Will the Current COVID-19 Pandemic Impact on Long-term Cannabis Buying Practices?Teodora Groshkova, Tiberiu Stoian, Andrew Cunningham, et al.Addiction (Abingdon, England)|October 1, 2015
The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015Jane Mounteney, Paul Griffiths, Roumen Sedefov, et al.Pageof 2